JP2010195828A5 - - Google Patents

Download PDF

Info

Publication number
JP2010195828A5
JP2010195828A5 JP2010126865A JP2010126865A JP2010195828A5 JP 2010195828 A5 JP2010195828 A5 JP 2010195828A5 JP 2010126865 A JP2010126865 A JP 2010126865A JP 2010126865 A JP2010126865 A JP 2010126865A JP 2010195828 A5 JP2010195828 A5 JP 2010195828A5
Authority
JP
Japan
Prior art keywords
solvate
showing
viii
formula
diphenylacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010126865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010195828A (ja
Filing date
Publication date
Priority claimed from GBGB0207104.1A external-priority patent/GB0207104D0/en
Application filed filed Critical
Publication of JP2010195828A publication Critical patent/JP2010195828A/ja
Publication of JP2010195828A5 publication Critical patent/JP2010195828A5/ja
Pending legal-status Critical Current

Links

JP2010126865A 2002-03-26 2010-06-02 ムスカリン性レセプターアンタゴニストの安定水和物 Pending JP2010195828A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003578353A Division JP2005524678A (ja) 2002-03-26 2003-03-17 ムスカリン性レセプターアンタゴニストの安定水和物

Publications (2)

Publication Number Publication Date
JP2010195828A JP2010195828A (ja) 2010-09-09
JP2010195828A5 true JP2010195828A5 (enExample) 2011-07-28

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003578353A Withdrawn JP2005524678A (ja) 2002-03-26 2003-03-17 ムスカリン性レセプターアンタゴニストの安定水和物
JP2010126865A Pending JP2010195828A (ja) 2002-03-26 2010-06-02 ムスカリン性レセプターアンタゴニストの安定水和物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003578353A Withdrawn JP2005524678A (ja) 2002-03-26 2003-03-17 ムスカリン性レセプターアンタゴニストの安定水和物

Country Status (22)

Country Link
US (3) US6930188B2 (enExample)
EP (2) EP2336124B1 (enExample)
JP (2) JP2005524678A (enExample)
KR (4) KR101026283B1 (enExample)
CN (1) CN100345840C (enExample)
AR (1) AR042608A1 (enExample)
AT (1) ATE495169T1 (enExample)
AU (1) AU2003209921A1 (enExample)
BR (2) BRPI0308706B8 (enExample)
CA (1) CA2480287C (enExample)
CY (2) CY1111200T1 (enExample)
DE (1) DE60335711D1 (enExample)
DK (2) DK2336124T3 (enExample)
ES (2) ES2358644T3 (enExample)
GB (1) GB0207104D0 (enExample)
PA (1) PA8569701A1 (enExample)
PT (2) PT1490357E (enExample)
SI (2) SI2336124T1 (enExample)
SV (1) SV2003001515A (enExample)
TW (1) TW200306816A (enExample)
UY (1) UY27735A1 (enExample)
WO (1) WO2003080599A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007076159A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090018346A1 (en) * 2007-07-13 2009-01-15 Medichem, S.A. Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
JP5450387B2 (ja) 2008-04-02 2014-03-26 株式会社カネカ (s)−3−(1−シアノ−1,1−ジフェニルメチル)−ピロリジンの製造法
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2018029140A1 (de) * 2016-08-12 2018-02-15 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von substituierten styrol-derivaten
WO2019053051A1 (en) * 2017-09-12 2019-03-21 Lts Lohmann Therapie-Systeme Ag MICRO NEEDLE IONTOPHORESIS DEVICE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Similar Documents

Publication Publication Date Title
JP2010195828A5 (enExample)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2014524442A5 (enExample)
FI2534153T4 (fi) 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja
JP2013509429A5 (enExample)
JP2011518833A5 (enExample)
JP2014502599A5 (enExample)
JP2009254428A5 (enExample)
JP2015522037A5 (enExample)
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
JP2015516425A5 (enExample)
JP2022037040A5 (enExample)
JP2015506987A5 (enExample)
JP2021517111A5 (enExample)
ME02102B (me) Novi polimorf
HRP20220031T1 (hr) Kristalni trihidratni oblik (3s,3s') 4,4'-disulfanedilbis (3-aminobutan 1-sulfonske kiseline)
RU2016104396A (ru) Лекарственные формы, соли и полиморфы транснорсертралина и их применения
JP2013520412A5 (enExample)
Lokhande et al. Microwave assisted synthesized bimetallic Ti and V based MXene for anticancer application
GB201220630D0 (en) Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldtjakob disease or diabetes mellitus
JP2016520122A5 (enExample)
IL273920B1 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP2018500355A5 (enExample)
Qin et al. Strong convergence for three classes of uniformly equi-continuous and asymptotically quasi-nonexpansive mappings
RU2016145264A (ru) Соли и полиморфы замещенного имидазопиридинил-аминопиридина